Targeting B cells to modify MS, NMOSD, and MOGAD: Part 2

Ocrelizumab, rituximab, ofatumumab, ublituximab, inebilizumab, and evobrutinib are immunotherapies that target various B cell–related proteins. Most of these treatments have proven efficacy in relapsing and progressive forms of MS and neuromyelitis optica spectrum disease (NMOSD) or are in advanced...

Descripción completa

Detalles Bibliográficos
Autores principales: Graf, Jonas, Mares, Jan, Barnett, Michael, Aktas, Orhan, Albrecht, Philipp, Zamvil, Scott S., Hartung, Hans-Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
Views & Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8063618/
https://www.ncbi.nlm.nih.gov/pubmed/33411674
http://dx.doi.org/10.1212/NXI.0000000000000919

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8063618/
https://www.ncbi.nlm.nih.gov/pubmed/33411674
http://dx.doi.org/10.1212/NXI.0000000000000919

Ejemplares similares